- Home
- WNEB vs HURA Comparison
WNEB vs HURA Comparison
Compare WNEB & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNEB
- HURA
- Stock Information
- Founded
- WNEB 1853
- HURA 2009
- Country
- WNEB United States
- HURA United States
- Employees
- WNEB N/A
- HURA N/A
- Industry
- WNEB Savings Institutions
- HURA
- Sector
- WNEB Finance
- HURA
- Exchange
- WNEB Nasdaq
- HURA Nasdaq
- Market Cap
- WNEB 188.7M
- HURA 193.8M
- IPO Year
- WNEB N/A
- HURA N/A
- Fundamental
- Price
- WNEB $9.12
- HURA $3.35
- Analyst Decision
- WNEB Hold
- HURA
- Analyst Count
- WNEB 3
- HURA 0
- Target Price
- WNEB $8.50
- HURA N/A
- AVG Volume (30 Days)
- WNEB 33.6K
- HURA 77.7K
- Earning Date
- WNEB 01-21-2025
- HURA 11-14-2024
- Dividend Yield
- WNEB 3.08%
- HURA N/A
- EPS Growth
- WNEB N/A
- HURA N/A
- EPS
- WNEB 0.52
- HURA N/A
- Revenue
- WNEB $72,500,000.00
- HURA N/A
- Revenue This Year
- WNEB N/A
- HURA N/A
- Revenue Next Year
- WNEB $6.24
- HURA N/A
- P/E Ratio
- WNEB $17.38
- HURA N/A
- Revenue Growth
- WNEB N/A
- HURA N/A
- 52 Week Low
- WNEB $6.00
- HURA $2.84
- 52 Week High
- WNEB $9.25
- HURA $17.36
- Technical
- Relative Strength Index (RSI)
- WNEB 59.10
- HURA N/A
- Support Level
- WNEB $8.84
- HURA N/A
- Resistance Level
- WNEB $8.97
- HURA N/A
- Average True Range (ATR)
- WNEB 0.15
- HURA 0.00
- MACD
- WNEB 0.02
- HURA 0.00
- Stochastic Oscillator
- WNEB 69.73
- HURA 0.00
About WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the Company's revenues, profits, and assets are derived by the Bank from banking products and services.
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.